A Phase 3 interventional study of Dasiglucagon and GlucaGen in Hypoglycemia and Diabetes Mellitus, Type 1, sponsored by Zealand Pharma. Completed at 5 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-10.
Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing dasiglucagon in Hypoglycemia — none open to participants now, none under way, none of them phase 3. dasiglucagon · Hypoglycemia.
Among the 16 studies testing dasiglucagon in Hypoglycemia, this one has the largest enrollment, is one of 2 that started in 2017, is one of 6 in phase 3, and was the 5th registered.
706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.
Browse Hypoglycemia studies →None of the 16 studies testing dasiglucagon in Hypoglycemia is open now. The open studies under Hypoglycemia, anywhere →
dasiglucagon: first FDA approval 2021 (ZEGALOGUE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 59 Hypoglycemia studies recruiting now, 23 (39%) set no upper age limit and 31 (53%) stop at 75 or younger; 18 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 170 is above the median of 28 across 534 interventional studies indexed under Hypoglycemia.
Median enrollment 33 across the 16 interventional studies. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 16 have an industry lead sponsor. The 5 most frequent:
Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
11 studies in Hypoglycemia by Zealand Pharma: none open now, none under way, none of them phase 3. Of 10 finished, 5 (50%) have results posted.
Among the 11 studies in Hypoglycemia by Zealand Pharma, this one has the largest enrollment, is one of 2 that started in 2017, is one of 6 in phase 3, and was the 5th registered.
Zealand Pharma’s Hypoglycemia studies by the year they started, since 2014.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing dasiglucagon in Hypoglycemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Zealand Pharma’s 11 in Hypoglycemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the trial is to demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus (T1DM) with insulin-induced hypoglycemia. Additionally to compare the glycemic response observed after administration dasiglucagon with that of GlucaGen®.
This was a global, multicenter, randomized, parallel, and double-blind clinical trial confirming the efficacy and safety of dasiglucagon for insulin-induced hypoglycemia in patients with T1DM. The patients were randomized 2:1:1 to receive a single subcutaneous 0.6 mg dose of dasiglucagon, placebo, or a 1 mg dose of GlucaGen and followed for at least 28 days after receiving treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single fixed dose (s.c.injection) of dasiglucagon
Drug: Dasiglucagon
Single fixed dose (s.c.injection) of placebo
Drug: Placebo
Single fixed dose (s.c.injection) of GlucaGen®
Drug: GlucaGen
Glucagon analog
Also known as: ZP4207
Native glucagon
Also known as: GlucaGen HypoKit
Placebo for dasiglucagon
Also known as: Placebo for dasiglucagon
Time to Plasma Glucose Recovery
Plasma glucose recovery is defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.
Time frame: 0-45 minutes after dosing
Plasma Glucose Recovery
Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after study drug injection without administration of rescue IV glucose. Plasma glucose recovery was defined as the first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose.
Time frame: 0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection
Plasma Glucose Changes From Baseline
Plasma glucose changes from baseline at 30 minutes, 20 minutes, 15 minutes and 10 minutes after study drug injection without administration of rescue intravenous glucose
Time frame: 0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection
Time to Target
Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.
Time frame: 0-45 minutes after dosing
Pharmacodynamics - Area Under the Effect Curve
Plasma glucose response as area under the effect curve (AUE) above baseline from time zero to 30 minutes. Samples were collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25 and 30 minutes after dosing.
Time frame: 0-30 minutes after dosing
Pharmacokinetics - Area Under the Plasma Concentration Curve
Area under the drug concentration curve from time zero to 90 minutes, AUC0-90min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
Time frame: 0-90 minutes after dosing
Pharmacokinetics - Area Under the Plasma Concentration Curve
Area under the drug concentration curve from time zero to 120 minutes, AUC0-120min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
Time frame: 0-120 minutes after dosing
Pharmacokinetics - Maximum Plasma Concentration
Maximum plasma drug concentration (Cmax). Maximum plasma drug concentration was determined as the maximum of all valid plasma dasiglucagon/glucagon concentrations. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
Time frame: 0-120 minutes after dosing
Pharmacokinetics - Time to Maximum Plasma Concentration
Time to maximum plasma drug concentration (tmax). Median Tmax was determined as the time point where the maximum of all valid plasma dasiglucagon/glucagon concentration measurements for each measurement series was observed. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
Time frame: 0-120 minutes after dosing
Immunogenicity - Occurence of Anti-drug Antibodies
Occurence of antibodies against dasiglucagon/GlucaGen
Time frame: 28 days
Rescue Infusion of IV Glucose During the Hypoglycemic Clamp Procedure
Number of patients receiving administration of rescue infusion of IV glucose during the hypoglycemic clamp procedure. IV = intravenous
Time frame: 0-45 minutes after dosing
Time to First Rescue Infusion of IV Glucose
Time to first rescue administration of rescue infusion of IV glucose. IV = intravenous
Time frame: 0-45 minutes after dosing
| Milestone | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg |
|---|---|---|---|
| Started | 84 | 43 | 43 |
| Randomized and exposed to treatment | 82 | 43 | 43 |
| Completed | 82 | 43 | 43 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
Plasma glucose recovery is defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.
| minutes | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg |
|---|---|---|---|
| Time to Plasma Glucose Recovery | 10 (10 to 10) | 40 (30 to 40) | 12 (10 to 12) |
Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after study drug injection without administration of rescue IV glucose. Plasma glucose recovery was defined as the first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose.
| Participants | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg |
|---|---|---|---|
| Glucose recovery at 30 minutes | 82 | 20 | 43 |
| Glucose recovery at 20 minutes | 81 | 6 | 42 |
| Glucose recovery at 15 minutes | 81 | 1 | 41 |
| Glucose recovery at 10 minutes | 53 | 0 | 21 |
Plasma glucose changes from baseline at 30 minutes, 20 minutes, 15 minutes and 10 minutes after study drug injection without administration of rescue intravenous glucose
| mg/dL | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg |
|---|---|---|---|
| At 30 minutes | 90.9 ± 18.2 | 19.1 ± 13.0 | 88.5 ± 19.2 |
| At 20 minutes | 59.7 ± 15.0 | 8.7 ± 10.8 | 58.4 ± 15.6 |
| At 15 minutes | 43.5 ± 12.51 | 6.65 ± 6.82 | 44.1 ± 14.0 |
| At 10 minutes | 23.9 ± 9.84 | -0.14 ± 5.65 | 22.0 ± 10.0 |
Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.
| minutes | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg |
|---|---|---|---|
| Time to Target | 8 (8 to 8) | 25 (20 to 30) | 8 (8 to 10) |
Plasma glucose response as area under the effect curve (AUE) above baseline from time zero to 30 minutes. Samples were collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25 and 30 minutes after dosing.
| mg*h/dL | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg |
|---|---|---|---|
| Pharmacodynamics - Area Under the Effect Curve | 21.0 ± 5.26 | 3.57 ± 2.86 | 20.4 ± 5.49 |
Area under the drug concentration curve from time zero to 90 minutes, AUC0-90min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
| pmol*h/L | Dasiglucagon 0.6 mg | GlucaGen® 1.0 mg |
|---|---|---|
| Pharmacokinetics - Area Under the Plasma Concentration Curve | 1430 ± 34.2 | 1300 ± 27.5 |
Area under the drug concentration curve from time zero to 120 minutes, AUC0-120min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
| pmol*h/L | Dasiglucagon 0.6 mg | GlucaGen® 1.0 mg |
|---|---|---|
| Pharmacokinetics - Area Under the Plasma Concentration Curve | 1770 ± 31.2 | 1490 ± 27.2 |
Maximum plasma drug concentration (Cmax). Maximum plasma drug concentration was determined as the maximum of all valid plasma dasiglucagon/glucagon concentrations. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
| pmol/L | Dasiglucagon 0.6 mg | GlucaGen® 1.0 mg |
|---|---|---|
| Pharmacokinetics - Maximum Plasma Concentration | 1280 ± 37.7 | 1490 ± 34.5 |
Time to maximum plasma drug concentration (tmax). Median Tmax was determined as the time point where the maximum of all valid plasma dasiglucagon/glucagon concentration measurements for each measurement series was observed. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.
| hours | Dasiglucagon 0.6 mg | GlucaGen® 1.0 mg |
|---|---|---|
| Pharmacokinetics - Time to Maximum Plasma Concentration | 0.670 (0.250 to 1.00) | 0.250 (0.230 to 0.670) |
Occurence of antibodies against dasiglucagon/GlucaGen
| Participants | Dasiglucagon 0.6 mg | GlucaGen® 1.0 mg |
|---|---|---|
| Anti-drug antibodies at follow-up day 28 | 1 | 0 |
| Anti-drug antibodies at second follow up | 0 | 0 |
Number of patients receiving administration of rescue infusion of IV glucose during the hypoglycemic clamp procedure. IV = intravenous
| Participants | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg |
|---|---|---|---|
| Rescue Infusion of IV Glucose During the Hypoglycemic Clamp Procedure | 0 | 0 | 0 |
Time to first rescue administration of rescue infusion of IV glucose. IV = intravenous
No measurements were reported for this outcome.
Collected over Adverse events (AEs) were collected from the first trial-related activity after the patient had signed the informed consent to the end of the follow-up period, i.e. over 28 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dasiglucagon 0.6 mg | 0/82 (0%) | 0/82 (0%) | 66/82 (80.5%) |
| Placebo | 0/43 (0%) | 0/43 (0%) | 14/43 (32.6%) |
| GlucaGen® 1.0 mg | 0/43 (0%) | 0/43 (0%) | 32/43 (74.4%) |
| Event | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 45/82 | 1/43 | 23/43 |
| HypoglycemiaMetabolism and nutrition disorders | 23/82 | 5/43 | 9/43 |
| VomitingGastrointestinal disorders | 19/82 | 1/43 | 9/43 |
| HeadacheNervous system disorders | 10/82 | 2/43 | 5/43 |
| NasopharyngitisInfections and infestations | 5/82 | 1/43 | 0/43 |
| DiarrheaGastrointestinal disorders | 4/82 | 0/43 | 1/43 |
| Injection site erythemaGeneral disorders | 1/82 | 2/43 | 2/43 |
| DizzinessNervous system disorders | 0/82 | 0/43 | 2/43 |
| PharyngitisInfections and infestations | 2/82 | 0/43 | 0/43 |
| Back painMusculoskeletal and connective tissue disorders | 2/82 | 0/43 | 0/43 |
| Age, Continuous(years) | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg | Total |
|---|---|---|---|---|
| Mean | 39.2 ± 12.1 | 38.0 ± 13.1 | 40.2 ± 11.5 | 39.1 ± 12.2 |
| Sex: Female, Male(Participants) | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg | Total |
|---|---|---|---|---|
| Female | 32 | 16 | 15 | 63 |
| Male | 50 | 27 | 28 | 105 |
| Ethnicity (NIH/OMB)(Participants) | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 3 | 7 |
| Not Hispanic or Latino | 80 | 41 | 40 | 161 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 3 | 2 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 1 | 1 | 2 | 4 |
| White | 76 | 39 | 39 | 154 |
| More than one race | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Region of Enrollment(participants) | Dasiglucagon 0.6 mg | Placebo | GlucaGen® 1.0 mg | Total |
|---|---|---|---|---|
| Canada | 18 | 10 | 10 | 38 |
| Austria | 33 | 0 | 0 | 33 |
| United States | 12 | 6 | 6 | 24 |
| Germany | 19 | 27 | 27 | 73 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Apr 2018, 4 months.
Results were first posted in May 2021, 3 years after primary completion. A results delay was requested in May 2019.
Of 17 phase 3 interventional studies under Hypoglycemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dasiglucagon